Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21351461,K,"In vivo fluorescence imaging system was applied to investigate the characteristics of cornea retention, and the results indicated that the nanoemulsion-in situ gel (NE-ISG) prolonged the cornea retention time significantly since K(NE-ISG) (0.008 5 min(-1) was much lower compared with flurbiprofen sodium eye drops (FB-Na, 0.03% w/v) of which the K(Eye drops) was 0.105 2 min(-1), indicated that the cornea retention time of NE-ISG was prolonged significantly.",[Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351461/),1/[min],0.008 5,124,DB00712,Flurbiprofen
,21351461,K,"In vivo fluorescence imaging system was applied to investigate the characteristics of cornea retention, and the results indicated that the nanoemulsion-in situ gel (NE-ISG) prolonged the cornea retention time significantly since K(NE-ISG) (0.008 5 min(-1) was much lower compared with flurbiprofen sodium eye drops (FB-Na, 0.03% w/v) of which the K(Eye drops) was 0.105 2 min(-1), indicated that the cornea retention time of NE-ISG was prolonged significantly.",[Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351461/),1/[min],0.105 2,125,DB00712,Flurbiprofen
,21351461,MRT,"Pharmacokinetics of FBA/NE-ISG in rabbit aqueous humor was studied by cornea puncture, the MRT (12.3 h) and AUC(0-12h) (126.8 microg x min x mL(-1)) of FBA/NE-ISG was 2.7 and 2.9 times higher than that of the flurbiprofen sodium eye drops respectively, which meant that the ocular bioavailability was improved greatly by the novel preparation.",[Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351461/),h,12.3,126,DB00712,Flurbiprofen
,21351461,AUC(0-12h),"Pharmacokinetics of FBA/NE-ISG in rabbit aqueous humor was studied by cornea puncture, the MRT (12.3 h) and AUC(0-12h) (126.8 microg x min x mL(-1)) of FBA/NE-ISG was 2.7 and 2.9 times higher than that of the flurbiprofen sodium eye drops respectively, which meant that the ocular bioavailability was improved greatly by the novel preparation.",[Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351461/),[min·μg] / [ml],126.8,127,DB00712,Flurbiprofen
,25820260,extraction recoveries,The extraction recoveries of flurbiprofen from human plasma were between 93.0 and 98.9%.,Determination of Flurbiprofen in Human Plasma by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25820260/),%,93.0 and 98.9,661,DB00712,Flurbiprofen
,25820260,limits of detection,"The limits of detection and quantification of flurbiprofen were 0.03 and 0.10 μg/mL, respectively.",Determination of Flurbiprofen in Human Plasma by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25820260/),[μg] / [ml],0.03,662,DB00712,Flurbiprofen
,25820260,limits of detection,"The limits of detection and quantification of flurbiprofen were 0.03 and 0.10 μg/mL, respectively.",Determination of Flurbiprofen in Human Plasma by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25820260/),[μg] / [ml],0.10,663,DB00712,Flurbiprofen
,23777257,Km,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,33,1718,DB00712,Flurbiprofen
,23777257,Vmax,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),1/[min],0.20,1719,DB00712,Flurbiprofen
,23777257,inhibition constant,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,37,1720,DB00712,Flurbiprofen
,23777257,maximum plasma concentration,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,10.5,1721,DB00712,Flurbiprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,90.1,2051,DB00712,Flurbiprofen
,8398601,recovery,"The recovery of total KT in bile was significantly higher after administration of (S)-KT than after (R)-KT [90.1 +/- 3.5% vs 68.8 +/- 8.2%, n = 3, P < 0.05].",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),%,68.8,2052,DB00712,Flurbiprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,2.2,2053,DB00712,Flurbiprofen
,8398601,terminal half-life,"In normal rats the terminal half-life of (R)-KT was significantly shorter than that of (S)-KT after administration of (R)-KT (2.2 +/- 0.6 h vs 14.3 +/- 4.9 h, n = 3, P < 0.05).",Stereoselectivity of biliary excretion of 2-arylpropionates in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398601/),h,14.3,2054,DB00712,Flurbiprofen
,25231972,maximum concentration,"The maximum concentration of FP in rats muscle was 2.03 μg/g and 1.55 μg/g after oral and topical administration, respectively.","Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25231972/),[μg] / [g],2.03,6023,DB00712,Flurbiprofen
,25231972,maximum concentration,"The maximum concentration of FP in rats muscle was 2.03 μg/g and 1.55 μg/g after oral and topical administration, respectively.","Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25231972/),[μg] / [g],1.55,6024,DB00712,Flurbiprofen
,25231972,peak concentration,While the peak concentration in untreated muscle after topical administration was only 0.37 μg/mL.,"Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25231972/),[μg] / [ml],0.37,6025,DB00712,Flurbiprofen
,22922591,t(1/2z),CHF5074 reached peak plasma levels 2 to 3 hours after drug administration and then was slowly eliminated (t(1/2z)=30 h) in the urine as glucoronide.,Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22922591/),h,30,24971,DB00712,Flurbiprofen
,8809639,time to reach maximum concentration (tmax),"Both S- and R-flurbiprofen were rapidly absorbed, with a time to reach maximum concentration (tmax) of 1.2 to 1.4 hours.","Human plasma concentrations of R, S, and racemic flurbiprofen given as a toothpaste. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8809639/),h,1.2 to 1.4,29778,DB00712,Flurbiprofen
,10727127,Recovery,Recovery of both INDB enantiomers was in the range 92.1-94.3%.,LC procedure with SPE for quantification of indobufen enantiomers: pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10727127/),%,92.1-94.3,39802,DB00712,Flurbiprofen
,17292621,IC(50)s,"In vitro, CHF5022 and CHF5074 were found to be 3- and 7-fold more potent than R-flurbiprofen in inhibiting Abeta42 secretion (IC(50)s of 92, 40 and 268microM, respectively).",In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292621/),μM,92,41506,DB00712,Flurbiprofen
,17292621,IC(50)s,"In vitro, CHF5022 and CHF5074 were found to be 3- and 7-fold more potent than R-flurbiprofen in inhibiting Abeta42 secretion (IC(50)s of 92, 40 and 268microM, respectively).",In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292621/),μM,40,41507,DB00712,Flurbiprofen
,17292621,IC(50)s,"In vitro, CHF5022 and CHF5074 were found to be 3- and 7-fold more potent than R-flurbiprofen in inhibiting Abeta42 secretion (IC(50)s of 92, 40 and 268microM, respectively).",In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292621/),μM,268,41508,DB00712,Flurbiprofen
,2015160,oral plasma clearance,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for R(-)-flurbiprofen were 0.075 (+/- 0.066) l min-1, 12.47 (+/- 5.79) l and 138 (+/- 61) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),[l] / [min],0.075,44235,DB00712,Flurbiprofen
,2015160,volume of distribution,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for R(-)-flurbiprofen were 0.075 (+/- 0.066) l min-1, 12.47 (+/- 5.79) l and 138 (+/- 61) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),l,12.47,44236,DB00712,Flurbiprofen
,2015160,elimination half-life,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for R(-)-flurbiprofen were 0.075 (+/- 0.066) l min-1, 12.47 (+/- 5.79) l and 138 (+/- 61) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),min,138,44237,DB00712,Flurbiprofen
,2015160,oral plasma clearance,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for S(+)-flurbiprofen were 0.057 (+/- 0.035) l min-1, 12.81 (+/- 4.43) l and 155 (+/- 49) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),[l] / [min],0.057,44238,DB00712,Flurbiprofen
,2015160,volume of distribution,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for S(+)-flurbiprofen were 0.057 (+/- 0.035) l min-1, 12.81 (+/- 4.43) l and 155 (+/- 49) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),l,12.81,44239,DB00712,Flurbiprofen
,2015160,elimination half-life,"The average values (+/- s.d.) of oral plasma clearance, volume of distribution and elimination half-life for S(+)-flurbiprofen were 0.057 (+/- 0.035) l min-1, 12.81 (+/- 4.43) l and 155 (+/- 49) min, respectively.",The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),min,155,44240,DB00712,Flurbiprofen
,2015160,S(+)/R(-) ratios,S(+)/R(-) ratios (+/- s.d.) rose from 1.06 (+/- 0.12) to 1.75 (+/- 0.61) at the end of the 12 h interval in plasma and from 1.18 (+/- 0.13) to 1.47 (+/- 0.24) over the measured time course in synovial fluid.,The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),,1.06,44241,DB00712,Flurbiprofen
,2015160,S(+)/R(-) ratios,S(+)/R(-) ratios (+/- s.d.) rose from 1.06 (+/- 0.12) to 1.75 (+/- 0.61) at the end of the 12 h interval in plasma and from 1.18 (+/- 0.13) to 1.47 (+/- 0.24) over the measured time course in synovial fluid.,The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),,1.75,44242,DB00712,Flurbiprofen
,2015160,S(+)/R(-) ratios,S(+)/R(-) ratios (+/- s.d.) rose from 1.06 (+/- 0.12) to 1.75 (+/- 0.61) at the end of the 12 h interval in plasma and from 1.18 (+/- 0.13) to 1.47 (+/- 0.24) over the measured time course in synovial fluid.,The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),,1.18,44243,DB00712,Flurbiprofen
,2015160,S(+)/R(-) ratios,S(+)/R(-) ratios (+/- s.d.) rose from 1.06 (+/- 0.12) to 1.75 (+/- 0.61) at the end of the 12 h interval in plasma and from 1.18 (+/- 0.13) to 1.47 (+/- 0.24) over the measured time course in synovial fluid.,The pharmacokinetics of the enantiomers of flurbiprofen in patients with rheumatoid arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015160/),,1.47,44244,DB00712,Flurbiprofen
,2257864,steady-state level,A mean steady-state level of approximately 6 micrograms/ml was achieved for both populations.,A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257864/),[μg] / [ml],6,49634,DB00712,Flurbiprofen
,2257864,pre-dose/peak range,Computer predicted data for 200 mg conventional flurbiprofen (as 100 mg b.d.) showed a pre-dose/peak range of 1-12 micrograms/ml.,A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257864/),[μg] / [ml],1-12,49635,DB00712,Flurbiprofen
,2257864,pre-dose/peak ranges,The pre-dose/peak ranges for the young and old patients were 4-10 micrograms/ml and 4-8 micrograms/ml respectively.,A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257864/),[μg] / [ml],4-10,49636,DB00712,Flurbiprofen
,2257864,pre-dose/peak ranges,The pre-dose/peak ranges for the young and old patients were 4-10 micrograms/ml and 4-8 micrograms/ml respectively.,A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257864/),[μg] / [ml],4-8,49637,DB00712,Flurbiprofen
,9131946,maximum,"After administration of R-flurbiprofen, there was a mean maximum TXB2 inhibition of 65.2 +/- 15.0% in serum but no significant changes of PGE2 levels in blister fluid were observed.",Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131946/),%,65.2,49883,DB00712,Flurbiprofen
,9131946,EC50,"For inhibition of TXB2 generation after administration of S-flurbiprofen, a sigmoidal log-linear concentration-response relationship was established in all subjects (EC50: 0.123 +/- 0.092 microgram ml-1).",Disposition and effects of flurbiprofen enantiomers in human serum and blister fluid. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131946/),[μg] / [ml],0.123,49884,DB00712,Flurbiprofen
,1576065,AUC,2. The AUC and half-life of the R-enantiomer were significantly lower than the corresponding S-enantiomer values reflecting the greater clearance of R-flurbiprofen (20.42 +/- 4.71 vs 16.12 +/- 3.60 ml min-1).,Stereoselective disposition of flurbiprofen in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576065/),[ml] / [min],20.42,53224,DB00712,Flurbiprofen
,1576065,clearance,2. The AUC and half-life of the R-enantiomer were significantly lower than the corresponding S-enantiomer values reflecting the greater clearance of R-flurbiprofen (20.42 +/- 4.71 vs 16.12 +/- 3.60 ml min-1).,Stereoselective disposition of flurbiprofen in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576065/),[ml] / [min],16.12,53225,DB00712,Flurbiprofen
,1576065,percent unbound,3. Ex vivo protein binding studies indicated that the percent unbound of R-flurbiprofen was (not significantly) greater than that of the S-enantiomer (0.055 +/- 0.008 vs 0.049 +/- 0.009) and the corresponding unbound clearances did not show enantioselectivity.,Stereoselective disposition of flurbiprofen in normal volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576065/),,0.055,53226,DB00712,Flurbiprofen
,1576065,percent unbound,3. Ex vivo protein binding studies indicated that the percent unbound of R-flurbiprofen was (not significantly) greater than that of the S-enantiomer (0.055 +/- 0.008 vs 0.049 +/- 0.009) and the corresponding unbound clearances did not show enantioselectivity.,Stereoselective disposition of flurbiprofen in normal volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576065/),,0.049,53227,DB00712,Flurbiprofen
,3954931,plasma clearance,"The average values for plasma clearance, volume of distribution and elimination halflife of flurbiprofen were 0.65 +/- 0.24 ml min-1 kg-1, 0.160 +/- 0.093 l kg-1 and 3.1 +/- 1.7 h, respectively.",Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954931/),[ml] / [kg·min],0.65,54201,DB00712,Flurbiprofen
,3954931,volume of distribution,"The average values for plasma clearance, volume of distribution and elimination halflife of flurbiprofen were 0.65 +/- 0.24 ml min-1 kg-1, 0.160 +/- 0.093 l kg-1 and 3.1 +/- 1.7 h, respectively.",Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954931/),[l] / [kg],0.160,54202,DB00712,Flurbiprofen
,3954931,elimination halflife,"The average values for plasma clearance, volume of distribution and elimination halflife of flurbiprofen were 0.65 +/- 0.24 ml min-1 kg-1, 0.160 +/- 0.093 l kg-1 and 3.1 +/- 1.7 h, respectively.",Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954931/),h,3.1,54203,DB00712,Flurbiprofen
,17654172,drug loading efficiency,The drug loading efficiency was 5.02% (w/w).,Preparation and evaluation of biodegradable flubiprofen gelatin micro-spheres for intra-articular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654172/),%,5.02,55126,DB00712,Flurbiprofen
,17654172,half time for 50% release,The half time for 50% release of FP from FP-GMS (t(50)) was 5.58 h.,Preparation and evaluation of biodegradable flubiprofen gelatin micro-spheres for intra-articular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654172/),h,5.58,55127,DB00712,Flurbiprofen
,2265238,elimination half-life,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),h,11.7,55831,DB00712,Flurbiprofen
,2265238,volume of distribution,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),[l] / [kg],0.12 to 0.22,55832,DB00712,Flurbiprofen
,2265238,total plasma clearance,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),[h·l] / [kg],0.017,55833,DB00712,Flurbiprofen
,2265238,time of maximum concentration,"After oral dosing, carprofen was rapidly absorbed (time of maximum concentration: 0.83 +/- 0.61 h) and comparison with the intravenous solution indicated complete bioavailability.","Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),h,0.83,55834,DB00712,Flurbiprofen
,2265238,Relative bioavailabilities,Relative bioavailabilities of the drug from the suppository were about 20 per cent lower than from rectal solutions.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),%,20,55835,DB00712,Flurbiprofen
,15451543,percent dissolved,"The percent dissolved at 1 h for Flu/beta-CD at pH 1.2 and 4.0 were 33.4 and 41.3%, respectively, and about 10 times larger than those for Flu.",Evaluation of the bioavailability of flurbiprofen and its beta-cyclodextrin inclusion complex in four different doses upon oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15451543/),%,33.4,62808,DB00712,Flurbiprofen
,15451543,percent dissolved,"The percent dissolved at 1 h for Flu/beta-CD at pH 1.2 and 4.0 were 33.4 and 41.3%, respectively, and about 10 times larger than those for Flu.",Evaluation of the bioavailability of flurbiprofen and its beta-cyclodextrin inclusion complex in four different doses upon oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15451543/),%,41.3,62809,DB00712,Flurbiprofen
,1576066,oral clearance,2. For R-flurbiprofen the oral clearance (mean +/- s.d.: 38.3 +/- 12.8 vs 30.8 +/- 11.5 ml min-1) and volume of distribution (Vz; 17.6 +/- 3.9 vs 14.6 +/- 2.5 l) were significantly greater (P less than 0.05) than for the S-enantiomer.,Stereoselective disposition of flurbiprofen in uraemic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576066/),[ml] / [min],38.3,64576,DB00712,Flurbiprofen
,1576066,oral clearance,2. For R-flurbiprofen the oral clearance (mean +/- s.d.: 38.3 +/- 12.8 vs 30.8 +/- 11.5 ml min-1) and volume of distribution (Vz; 17.6 +/- 3.9 vs 14.6 +/- 2.5 l) were significantly greater (P less than 0.05) than for the S-enantiomer.,Stereoselective disposition of flurbiprofen in uraemic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576066/),[ml] / [min],30.8,64577,DB00712,Flurbiprofen
,1576066,volume of distribution (Vz,2. For R-flurbiprofen the oral clearance (mean +/- s.d.: 38.3 +/- 12.8 vs 30.8 +/- 11.5 ml min-1) and volume of distribution (Vz; 17.6 +/- 3.9 vs 14.6 +/- 2.5 l) were significantly greater (P less than 0.05) than for the S-enantiomer.,Stereoselective disposition of flurbiprofen in uraemic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576066/),l,17.6,64578,DB00712,Flurbiprofen
,1576066,volume of distribution (Vz,2. For R-flurbiprofen the oral clearance (mean +/- s.d.: 38.3 +/- 12.8 vs 30.8 +/- 11.5 ml min-1) and volume of distribution (Vz; 17.6 +/- 3.9 vs 14.6 +/- 2.5 l) were significantly greater (P less than 0.05) than for the S-enantiomer.,Stereoselective disposition of flurbiprofen in uraemic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576066/),l,14.6,64579,DB00712,Flurbiprofen
,6510467,Half-life,"Half-life (2.7-3.2 h), elimination constant (0.22-0.26 h-1), area under the plasma level curve (72.4-77.3 micrograms X h X ml-1) and time to reach the concentration peak (1-0.75 h) were similar after the syrup and suppository.",Pharmacokinetics of oral and rectal flurbiprofen in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510467/),h,2.7-3.2,67324,DB00712,Flurbiprofen
,6510467,elimination constant,"Half-life (2.7-3.2 h), elimination constant (0.22-0.26 h-1), area under the plasma level curve (72.4-77.3 micrograms X h X ml-1) and time to reach the concentration peak (1-0.75 h) were similar after the syrup and suppository.",Pharmacokinetics of oral and rectal flurbiprofen in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510467/),1/[h],0.22-0.26,67325,DB00712,Flurbiprofen
,6510467,area under the plasma level curve,"Half-life (2.7-3.2 h), elimination constant (0.22-0.26 h-1), area under the plasma level curve (72.4-77.3 micrograms X h X ml-1) and time to reach the concentration peak (1-0.75 h) were similar after the syrup and suppository.",Pharmacokinetics of oral and rectal flurbiprofen in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510467/),[h·μg] / [ml],72.4-77.3,67326,DB00712,Flurbiprofen
,6510467,time to reach the concentration peak,"Half-life (2.7-3.2 h), elimination constant (0.22-0.26 h-1), area under the plasma level curve (72.4-77.3 micrograms X h X ml-1) and time to reach the concentration peak (1-0.75 h) were similar after the syrup and suppository.",Pharmacokinetics of oral and rectal flurbiprofen in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510467/),h,1-0.75,67327,DB00712,Flurbiprofen
,6664824,apparent pH,The organic solvent was evaporated and the residue dissolved in a water-methanol (2 + 3) phosphate buffer mixture with an apparent pH of 6.8.,Plasma indomethacin assay by reversed-phase ion pair high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664824/),,6.8,71370,DB00712,Flurbiprofen
,6664824,analytical recovery,"At a 2.0 mg X l-1 concentration of indomethacin in plasma the analytical recovery was 82.9 +/- 3.4% (n = 7), the intra-day variability (CV) was 3.6% (n = 7) and the inter-day variability (CV) was 11.0% (n = 7).",Plasma indomethacin assay by reversed-phase ion pair high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664824/),%,82.9,71371,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,15.6,74962,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,3.8,74963,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,20.1,74964,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,17.7,74965,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,6.6,74966,DB00712,Flurbiprofen
,23571427,K(m),The K(m) values for UGT1A9 (15.6 ± 1.6 mM for R-ornidazole) and 2B7 (3.8 ± 0.9 mM for S-ornidazole) were quite similar to those determined in HLMs and HKMs (20.1 ± 1.4 and 17.7 ± 4.0 mM for R-ornidazole; 6.6 ± 1.3 and 3.2 ± 0.4 mM for S-ornidazole).,Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),mM,3.2,74967,DB00712,Flurbiprofen
,23571427,intrinsic clearance (CL(int)) ratios,"The in vitro intrinsic clearance (CL(int)) ratios of S- to R-ornidazole were approximately 4.3 in HLMs and 6.5 in HKMs, respectively.",Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),,4.3,74968,DB00712,Flurbiprofen
,23571427,intrinsic clearance (CL(int)) ratios,"The in vitro intrinsic clearance (CL(int)) ratios of S- to R-ornidazole were approximately 4.3 in HLMs and 6.5 in HKMs, respectively.",Stereoselective glucuronidation of ornidazole in humans: predominant contribution of UDP-glucuronosyltransferases 1A9 and 2B7. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23571427/),,6.5,74969,DB00712,Flurbiprofen
,20637868,area under the plasma concentration-time curve (AUC),"Values for the area under the plasma concentration-time curve (AUC) of untreated PRO, SDPs of PRO/Hsp-G and PRO/Stevia-G after oral administration to rats were 4.94±2.06, 26.08±4.52 and 48.79±9.97μgh/mL, respectively.",Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637868/),[μgh] / [ml],4.94,75977,DB00712,Flurbiprofen
,20637868,area under the plasma concentration-time curve (AUC),"Values for the area under the plasma concentration-time curve (AUC) of untreated PRO, SDPs of PRO/Hsp-G and PRO/Stevia-G after oral administration to rats were 4.94±2.06, 26.08±4.52 and 48.79±9.97μgh/mL, respectively.",Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637868/),[μgh] / [ml],26.08,75978,DB00712,Flurbiprofen
,20637868,area under the plasma concentration-time curve (AUC),"Values for the area under the plasma concentration-time curve (AUC) of untreated PRO, SDPs of PRO/Hsp-G and PRO/Stevia-G after oral administration to rats were 4.94±2.06, 26.08±4.52 and 48.79±9.97μgh/mL, respectively.",Transglycosylated stevia and hesperidin as pharmaceutical excipients: dramatic improvement in drug dissolution and bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20637868/),[μgh] / [ml],48.79,75979,DB00712,Flurbiprofen
,33147873,absolute bioavailability,Flurbiprofen has absolute bioavailability of ~95% and linear pharmacokinetics in the dose range of 50-300 mg.,"Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33147873/),%,95,78683,DB00712,Flurbiprofen
,28402143,percentage cumulative release,"In addition, this improvement in dissolution was shown to be pH-independent (the percentage cumulative release at pH 1.2, 4.5, 6.8 and 7.4 at 5 min was 95.19 ± 1.71, 101.75 ± 1.44, 105.37 ± 4.58 and 96.84 ± 0.56, respectively).","A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402143/),,95.19,79917,DB00712,Flurbiprofen
,28402143,percentage cumulative release,"In addition, this improvement in dissolution was shown to be pH-independent (the percentage cumulative release at pH 1.2, 4.5, 6.8 and 7.4 at 5 min was 95.19 ± 1.71, 101.75 ± 1.44, 105.37 ± 4.58 and 96.84 ± 0.56, respectively).","A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402143/),,101.75,79918,DB00712,Flurbiprofen
,28402143,percentage cumulative release,"In addition, this improvement in dissolution was shown to be pH-independent (the percentage cumulative release at pH 1.2, 4.5, 6.8 and 7.4 at 5 min was 95.19 ± 1.71, 101.75 ± 1.44, 105.37 ± 4.58 and 96.84 ± 0.56, respectively).","A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402143/),,105.37,79919,DB00712,Flurbiprofen
,28402143,percentage cumulative release,"In addition, this improvement in dissolution was shown to be pH-independent (the percentage cumulative release at pH 1.2, 4.5, 6.8 and 7.4 at 5 min was 95.19 ± 1.71, 101.75 ± 1.44, 105.37 ± 4.58 and 96.84 ± 0.56, respectively).","A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28402143/),,96.84,79920,DB00712,Flurbiprofen
,24260738,C(max),The C(max) of colon targeted tablets was 11956.15 ng/mL at T max of 10 h whereas it was 15677.52 ng/mL at 3 h in case of immediate release tablets.,"Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),[ng] / [ml],11956.15,80060,DB00712,Flurbiprofen
,24260738,C(max),The C(max) of colon targeted tablets was 11956.15 ng/mL at T max of 10 h whereas it was 15677.52 ng/mL at 3 h in case of immediate release tablets.,"Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),[ng] / [ml],15677.52,80061,DB00712,Flurbiprofen
,24260738,T max,The C(max) of colon targeted tablets was 11956.15 ng/mL at T max of 10 h whereas it was 15677.52 ng/mL at 3 h in case of immediate release tablets.,"Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),h,10,80062,DB00712,Flurbiprofen
,24260738,T max,The C(max) of colon targeted tablets was 11956.15 ng/mL at T max of 10 h whereas it was 15677.52 ng/mL at 3 h in case of immediate release tablets.,"Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),[ng] / [ml],15677.52,80063,DB00712,Flurbiprofen
,24260738,area under the curve,"The area under the curve for the immediate release and compression coated tablets was 40385.78 and 78214.50 ng-h/mL and the mean resident time was 3.49 and 10.78 h, respectively.","Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),[ng-h] / [ml],40385.78,80064,DB00712,Flurbiprofen
,24260738,area under the curve,"The area under the curve for the immediate release and compression coated tablets was 40385.78 and 78214.50 ng-h/mL and the mean resident time was 3.49 and 10.78 h, respectively.","Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),[ng-h] / [ml],78214.50,80065,DB00712,Flurbiprofen
,24260738,resident time,"The area under the curve for the immediate release and compression coated tablets was 40385.78 and 78214.50 ng-h/mL and the mean resident time was 3.49 and 10.78 h, respectively.","Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),h,3.49,80066,DB00712,Flurbiprofen
,24260738,resident time,"The area under the curve for the immediate release and compression coated tablets was 40385.78 and 78214.50 ng-h/mL and the mean resident time was 3.49 and 10.78 h, respectively.","Colon targeted guar gum compression coated tablets of flurbiprofen: formulation, development, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24260738/),h,10.78,80067,DB00712,Flurbiprofen
,26304493,relative bioavailability,The in vivo study indicated that the relative bioavailability of the novel osmotic pump system was 133.99% compared with the commercial preparation.,A novel osmotic pump-based controlled delivery system consisting of pH-modulated solid dispersion for poorly soluble drug flurbiprofen: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26304493/),%,133.99,92408,DB00712,Flurbiprofen
,28147361,renal clearance,Its renal clearance was calculated to be 1.62 mL/min/kg.,Enantioselective Effect of Flurbiprofen on Lithium Disposition in Rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28147361/),[ml] / [kg·min],1.62,93482,DB00712,Flurbiprofen
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,10,96196,DB00712,Flurbiprofen
,11041263,systemic bioavailability,"The remaining FP in the gel 6 h after the application was 60% of the initial loading and the systemic bioavailability over the 6 h application was about 10%, suggesting that the rest (30%) had accumulated in the skin tissues.",Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11041263/),%,30,96197,DB00712,Flurbiprofen
,31878816,bioavailability,"Flurbiprofen (FP) is one of the most potent nonsteroidal anti-inflammatory drugs with very low bioavailability of approximately 12% following transdermal administration, compared to that after oral administration.","Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31878816/),%,12,100187,DB00712,Flurbiprofen
,31878816,enhancement ratio (ER),"Compared to that of FP solution, the enhancement ratio (ER) of FP-GEO-ME gel was 4.06.","Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31878816/),,4.06,100188,DB00712,Flurbiprofen
,31878816,relative bioavailability,"The relative bioavailability of FP and 1,8-cineole after transdermal administration compared to oral administration of FP-GEO-ME were determined to be 96.58% and 85.49%, respectively.","Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31878816/),%,96.58,100189,DB00712,Flurbiprofen
,31878816,relative bioavailability,"The relative bioavailability of FP and 1,8-cineole after transdermal administration compared to oral administration of FP-GEO-ME were determined to be 96.58% and 85.49%, respectively.","Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31878816/),%,85.49,100190,DB00712,Flurbiprofen
,26438533,percutaneous absorption ratio,"Study 1: The plasma concentration of SFP was sustained during 24-h topical application of the SFPP, showing a high percutaneous absorption ratio of 51.4-72.2 %.",Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26438533/),%,51.4-72.2,101271,DB00712,Flurbiprofen
,7736686,terminal phase elimination half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase elimination half-life of conventional immediate release flurbiprofen (3 to 6 hours).",Clinical pharmacokinetics of flurbiprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736686/),h,3 to 6,102250,DB00712,Flurbiprofen
,2749000,Cb/Cf ratio,"The Cb/Cf ratio averaged 1524, indicating that in plasma, flurbiprofen is greater than 99.9% bound.",Pharmacokinetics of flurbiprofen in man. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2749000/),,1524,102425,DB00712,Flurbiprofen
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,6.7,104991,DB00712,Flurbiprofen
,22900583,metabolic ratio (MR),"Midazolam metabolic ratio (MR) dramatically decreased in presence of ritonavir (6.7 ± 2.6 versus 0.13 ± 0.07) reflecting an almost complete inhibition of CYP3A4, whereas omeprazole, flurbiprofen and bupropion MR were not affected.",Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22900583/),,0.13,104992,DB00712,Flurbiprofen
,16474960,half-lives,"At 24 h after the final dosing, KP concentrations in the skin with R-KP and S-KP treatment were 187.4 and 254.7 microg/g, respectively, and their half-lives were 80.5 and 84.4 h, respectively.",Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),h,80.5,105102,DB00712,Flurbiprofen
,16474960,half-lives,"At 24 h after the final dosing, KP concentrations in the skin with R-KP and S-KP treatment were 187.4 and 254.7 microg/g, respectively, and their half-lives were 80.5 and 84.4 h, respectively.",Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),h,84.4,105103,DB00712,Flurbiprofen
,16474960,concentrations,KP concentrations at 336 h after final dosing were 11.3 microg/g for R-KP and 15.7 microg/g for S-KP treatment.,Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),[μg] / [g],11.3,105104,DB00712,Flurbiprofen
,16474960,concentrations,KP concentrations at 336 h after final dosing were 11.3 microg/g for R-KP and 15.7 microg/g for S-KP treatment.,Study on the mechanism of photosensitive dermatitis caused by ketoprofen in the guinea pig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16474960/),[μg] / [g],15.7,105105,DB00712,Flurbiprofen
,24916715,drug release,The optimized formulation showed negligible drug release (4.33 ± 0.06 %) in the initial lag period followed by progressive release (100.78 ± 0.64 %) for 24 h.,Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916715/),%,4.33,105326,DB00712,Flurbiprofen
,24916715,drug release,The optimized formulation showed negligible drug release (4.33 ± 0.06 %) in the initial lag period followed by progressive release (100.78 ± 0.64 %) for 24 h.,Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916715/),%,100,105327,DB00712,Flurbiprofen
,24916715,C max,"The C max of colon-targeted tablets was 12,374.67 ng/ml at T max 10 h, where as in case of immediate release tablets the C max was 15,677.52 ng/ml at T max 3 h, that signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916715/),[ng] / [ml],"12,374.67",105328,DB00712,Flurbiprofen
,24916715,C max,"The C max of colon-targeted tablets was 12,374.67 ng/ml at T max 10 h, where as in case of immediate release tablets the C max was 15,677.52 ng/ml at T max 3 h, that signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24916715/),[ng] / [ml],"15,677.52",105329,DB00712,Flurbiprofen
,1875281,clearance,"Population estimates for the plasma parameters, clearance, volume of distribution, and elimination half-life were 1.75 L hr-1, 11.9 L, and 4.8 hr, respectively, and the corresponding interindividual variances in these parameters were 29, 19 and 23%, respectively.",The kinetics of flurbiprofen in synovial fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875281/),[l] / [h],1.75,110542,DB00712,Flurbiprofen
,1875281,volume of distribution,"Population estimates for the plasma parameters, clearance, volume of distribution, and elimination half-life were 1.75 L hr-1, 11.9 L, and 4.8 hr, respectively, and the corresponding interindividual variances in these parameters were 29, 19 and 23%, respectively.",The kinetics of flurbiprofen in synovial fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875281/),l,11.9,110543,DB00712,Flurbiprofen
,1875281,elimination half-life,"Population estimates for the plasma parameters, clearance, volume of distribution, and elimination half-life were 1.75 L hr-1, 11.9 L, and 4.8 hr, respectively, and the corresponding interindividual variances in these parameters were 29, 19 and 23%, respectively.",The kinetics of flurbiprofen in synovial fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875281/),h,4.8,110544,DB00712,Flurbiprofen
,1875281,apparent elimination half-life,The apparent elimination half-life from synovial fluid was 7.1 hr.,The kinetics of flurbiprofen in synovial fluid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875281/),h,7.1,110545,DB00712,Flurbiprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,12,116211,DB00712,Flurbiprofen
,9356198,maximal effect,"The maximal effect lasted 12 and 36 h following 10 and 20 mg kg-1 doses, respectively.",Toxicokinetics of indomethacin-induced intestinal permeability in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356198/),h,36,116212,DB00712,Flurbiprofen
,11745747,loss,"Naproxen, which was shown to have a similar in vivo loss by retrodialysis as flurbiprofen (71.5 +/- 0.9% and 71.0 +/- 0.8% respectively, n = 3), was used to continuously monitor probe recovery.",Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745747/),%,71.5,120394,DB00712,Flurbiprofen
,11745747,loss,"Naproxen, which was shown to have a similar in vivo loss by retrodialysis as flurbiprofen (71.5 +/- 0.9% and 71.0 +/- 0.8% respectively, n = 3), was used to continuously monitor probe recovery.",Validation of subcutaneous microdialysis sampling for pharmacokinetic studies of flurbiprofen in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745747/),%,71.0,120395,DB00712,Flurbiprofen
,11457649,plasma concentrations,Dapsone plasma concentrations averaged 5 +/- 2 microM after a single dose and 11 +/- 4 microM after seven daily 100 mg doses.,Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457649/),μM,5,122919,DB00712,Flurbiprofen
,11457649,plasma concentrations,Dapsone plasma concentrations averaged 5 +/- 2 microM after a single dose and 11 +/- 4 microM after seven daily 100 mg doses.,Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11457649/),μM,11,122920,DB00712,Flurbiprofen
,19462921,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of FLU 19,143.65 ng/ml and 19,164.22 ng/ml were found for test and reference formulation respectively.",Clinical study on the bioequivalence of two tablet formulations of flurbiprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19462921/),[ng] / [ml],"19,143.65",127248,DB00712,Flurbiprofen
,19462921,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of FLU 19,143.65 ng/ml and 19,164.22 ng/ml were found for test and reference formulation respectively.",Clinical study on the bioequivalence of two tablet formulations of flurbiprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19462921/),[ng] / [ml],"19,164.22",127249,DB00712,Flurbiprofen
,19462921,Areas under the plasma concentration time curve AUC(0-infinity),"Areas under the plasma concentration time curve AUC(0-infinity), of 118 501.4 ng.h/ml and 111,339.8 ng.h/ml were calculated test and reference formulation respectively.",Clinical study on the bioequivalence of two tablet formulations of flurbiprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19462921/),[h·ng] / [ml],118 501.4,127250,DB00712,Flurbiprofen
,19462921,Areas under the plasma concentration time curve AUC(0-infinity),"Areas under the plasma concentration time curve AUC(0-infinity), of 118 501.4 ng.h/ml and 111,339.8 ng.h/ml were calculated test and reference formulation respectively.",Clinical study on the bioequivalence of two tablet formulations of flurbiprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19462921/),[h·ng] / [ml],"111,339.8",127251,DB00712,Flurbiprofen
,14555340,apparent elimination half-life,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,5.2,127356,DB00712,Flurbiprofen
,14555340,apparent elimination half-life,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,4.5,127357,DB00712,Flurbiprofen
,14555340,apparent elimination half-life,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,9.6,127358,DB00712,Flurbiprofen
,14555340,apparent elimination half-life,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,7.1,127359,DB00712,Flurbiprofen
,14555340,S,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,9.6,127360,DB00712,Flurbiprofen
,14555340,S,"3. Modest enantioselectivity in clearance (CL S/R: young, 0.86; elderly, 0.88) was largely responsible for the apparent elimination half-life of (S)-flurbiprofen being significantly greater (p<0.01) than that of the R-enantiomer in both age groups (young, S: 5.2 +/- 0.7 versus R: 4.5 +/- 0.6 h; elderly, S: 9.6 +/- 1.2 versus R: 7.1 +/- 1.0 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,7.1,127361,DB00712,Flurbiprofen
,14555340,apparent half-lives,"The serum concentrations of 4'-hydroxyflurbiprofen were five- to 20-fold lower than those of the corresponding drug enantiomers, stereoselective disposition being evident in the significantly greater (p<0.05) apparent half-lives of the S- compared with the R-enantiomer in both groups (young, S: 10.6 +/- 2.4 versus R: 6.7 +/- 1.1 h; elderly, S: 13.7 +/- 1.7 versus R: 10.2 +/- 1.2 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,10.6,127362,DB00712,Flurbiprofen
,14555340,apparent half-lives,"The serum concentrations of 4'-hydroxyflurbiprofen were five- to 20-fold lower than those of the corresponding drug enantiomers, stereoselective disposition being evident in the significantly greater (p<0.05) apparent half-lives of the S- compared with the R-enantiomer in both groups (young, S: 10.6 +/- 2.4 versus R: 6.7 +/- 1.1 h; elderly, S: 13.7 +/- 1.7 versus R: 10.2 +/- 1.2 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,6.7,127363,DB00712,Flurbiprofen
,14555340,apparent half-lives,"The serum concentrations of 4'-hydroxyflurbiprofen were five- to 20-fold lower than those of the corresponding drug enantiomers, stereoselective disposition being evident in the significantly greater (p<0.05) apparent half-lives of the S- compared with the R-enantiomer in both groups (young, S: 10.6 +/- 2.4 versus R: 6.7 +/- 1.1 h; elderly, S: 13.7 +/- 1.7 versus R: 10.2 +/- 1.2 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,13.7,127364,DB00712,Flurbiprofen
,14555340,apparent half-lives,"The serum concentrations of 4'-hydroxyflurbiprofen were five- to 20-fold lower than those of the corresponding drug enantiomers, stereoselective disposition being evident in the significantly greater (p<0.05) apparent half-lives of the S- compared with the R-enantiomer in both groups (young, S: 10.6 +/- 2.4 versus R: 6.7 +/- 1.1 h; elderly, S: 13.7 +/- 1.7 versus R: 10.2 +/- 1.2 h).",Disposition of flurbiprofen in man: influence of stereochemistry and age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14555340/),h,10.2,127365,DB00712,Flurbiprofen
,23493109,maximum percent edema inhibition,The maximum percent edema inhibition (58%) and significant analgesic effect of 13 s were determined for SLs.,"Flurbiprofen-loaded stealth liposomes: studies on the development, characterization, pharmacokinetics, and biodistribution. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493109/),%,58,128112,DB00712,Flurbiprofen
,21361044,V1 (L),"The basic model was described as follows: CL (L x h(-1)) = 1.28x EXP(ETA(1)), V1 (L) = 5.03x EXP(ETA(2)), Q (L x h(-1)) = 8.5 x EXP(ETA(3)), V2 (L) = 4.39 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),,5.03,130044,DB00712,Flurbiprofen
,21361044,Q (,"The basic model was described as follows: CL (L x h(-1)) = 1.28x EXP(ETA(1)), V1 (L) = 5.03x EXP(ETA(2)), Q (L x h(-1)) = 8.5 x EXP(ETA(3)), V2 (L) = 4.39 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),[l] / [h],8.5,130045,DB00712,Flurbiprofen
,21361044,V2 (L),"The basic model was described as follows: CL (L x h(-1)) = 1.28x EXP(ETA(1)), V1 (L) = 5.03x EXP(ETA(2)), Q (L x h(-1)) = 8.5 x EXP(ETA(3)), V2 (L) = 4.39 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),,4.39,130046,DB00712,Flurbiprofen
,21361044,V1,"The final model was described as follows: CL (L x h(-1)) = 1.32 x (WT/60) x EXP(ETA(1)), V1 (L) = 5.23 x (WT/60) x EXP(ETA(2)), Q (L x h(-1)) = 8.45 x EXP(ETA(3)), V2 (L) = 4.37 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),,5,130047,DB00712,Flurbiprofen
,21361044,Q,"The final model was described as follows: CL (L x h(-1)) = 1.32 x (WT/60) x EXP(ETA(1)), V1 (L) = 5.23 x (WT/60) x EXP(ETA(2)), Q (L x h(-1)) = 8.45 x EXP(ETA(3)), V2 (L) = 4.37 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),[l] / [h],8.45,130048,DB00712,Flurbiprofen
,21361044,V2 (L),"The final model was described as follows: CL (L x h(-1)) = 1.32 x (WT/60) x EXP(ETA(1)), V1 (L) = 5.23 x (WT/60) x EXP(ETA(2)), Q (L x h(-1)) = 8.45 x EXP(ETA(3)), V2 (L) = 4.37 x EXP(ETA(4)).",[Population pharmacokinetic modeling of flurbiprofen]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),,4.37,130049,DB00712,Flurbiprofen
,21361044,CL,"The population typical value of CL, V1, Q and V2 were: 1.32 L x h(-1), 5.23 L, 8.45 L x h(-1) and 4.37 L, respectively.",[Population pharmacokinetic modeling of flurbiprofen]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),[l] / [h],1.32,130050,DB00712,Flurbiprofen
,21361044,V1,"The population typical value of CL, V1, Q and V2 were: 1.32 L x h(-1), 5.23 L, 8.45 L x h(-1) and 4.37 L, respectively.",[Population pharmacokinetic modeling of flurbiprofen]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),l,5.23,130051,DB00712,Flurbiprofen
,21361044,V1,"The population typical value of CL, V1, Q and V2 were: 1.32 L x h(-1), 5.23 L, 8.45 L x h(-1) and 4.37 L, respectively.",[Population pharmacokinetic modeling of flurbiprofen]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),[l] / [h],8.45,130052,DB00712,Flurbiprofen
,21361044,Q,"The population typical value of CL, V1, Q and V2 were: 1.32 L x h(-1), 5.23 L, 8.45 L x h(-1) and 4.37 L, respectively.",[Population pharmacokinetic modeling of flurbiprofen]. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),l,5.23,130053,DB00712,Flurbiprofen
,21361044,V2,"The population typical value of CL, V1, Q and V2 were: 1.32 L x h(-1), 5.23 L, 8.45 L x h(-1) and 4.37 L, respectively.",[Population pharmacokinetic modeling of flurbiprofen]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21361044/),l,4.37,130054,DB00712,Flurbiprofen
,3210154,AUC,"Upon iv administration of 10 mg/kg of racemic flurbiprofen to male Sprague-Dawley rats, the plasma concentrations were consistently higher for S-flurbiprofen than for R-flurbiprofen (AUC = 134 +/- 39 versus 41 +/- 9 mg.L-1 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[h·mg] / [l],134,134013,DB00712,Flurbiprofen
,3210154,AUC,"Upon iv administration of 10 mg/kg of racemic flurbiprofen to male Sprague-Dawley rats, the plasma concentrations were consistently higher for S-flurbiprofen than for R-flurbiprofen (AUC = 134 +/- 39 versus 41 +/- 9 mg.L-1 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[h·mg] / [l],41,134014,DB00712,Flurbiprofen
,3210154,AUC-(S):AUC(R),"In healthy volunteers also, significant stereoselectivity was observed in the plasma concentration of the drug after 100-mg oral racemic doses [AUC-(S):AUC(R) = 45.4 +/- 12.7:40.1 +/- 14.3 mg.L-1.h].",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[h·mg] / [l],45.4,134015,DB00712,Flurbiprofen
,3210154,AUC-(S):AUC(R),"In healthy volunteers also, significant stereoselectivity was observed in the plasma concentration of the drug after 100-mg oral racemic doses [AUC-(S):AUC(R) = 45.4 +/- 12.7:40.1 +/- 14.3 mg.L-1.h].",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[h·mg] / [l],40.1,134016,DB00712,Flurbiprofen
,3210154,volume of distribution,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),l,7.23,134017,DB00712,Flurbiprofen
,3210154,volume of distribution,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),l,8.41,134018,DB00712,Flurbiprofen
,3210154,total clearance,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[l] / [h],1.23,134019,DB00712,Flurbiprofen
,3210154,total clearance,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),[l] / [h],1.47,134020,DB00712,Flurbiprofen
,3210154,half-life,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),h,4.21,134021,DB00712,Flurbiprofen
,3210154,half-life,"As compared with the R-enantiomer, S-flurbiprofen has a smaller volume of distribution (7.23 +/- 1.9 versus 8.41 +/- 3.0 L) and total clearance (1.23 +/- 0.34 versus 1.47 +/- 0.50 L/h), but an equal half-life (4.21 +/- 1.2 versus 4.18 +/- 1.3 h).",Stereoselective pharmacokinetics of flurbiprofen in humans and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3210154/),h,4.18,134022,DB00712,Flurbiprofen
,25994482,permeation,ISO-C10 could increase the in-vitro permeation of flurbiprofen from 46.22 ± 5.65 μg/cm(2) to 101.07 ± 10.85 μg/cm(2) .,Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25994482/),[μg] / [cm(2],46.22,135158,DB00712,Flurbiprofen
,25994482,permeation,ISO-C10 could increase the in-vitro permeation of flurbiprofen from 46.22 ± 5.65 μg/cm(2) to 101.07 ± 10.85 μg/cm(2) .,Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25994482/),[μg] / [cm(2],101.07,135159,DB00712,Flurbiprofen
,30555252,θKe,"Population mean values of PK parameters estimated in the final model were θKe =0.0015/h, θVd =7.91 L, and θCL =1.55 L/h.","Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30555252/),1/[h],0.0015,139556,DB00712,Flurbiprofen
,30555252,θVd,"Population mean values of PK parameters estimated in the final model were θKe =0.0015/h, θVd =7.91 L, and θCL =1.55 L/h.","Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30555252/),l,7.91,139557,DB00712,Flurbiprofen
,30555252,θCL,"Population mean values of PK parameters estimated in the final model were θKe =0.0015/h, θVd =7.91 L, and θCL =1.55 L/h.","Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30555252/),[l] / [h],1.55,139558,DB00712,Flurbiprofen
,1804864,urinary recovery,"Mean urinary recovery of the dose was 73% in the normal subjects, but only 16% in ESRD subjects.",Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804864/),%,73,140505,DB00712,Flurbiprofen
,1804864,urinary recovery,"Mean urinary recovery of the dose was 73% in the normal subjects, but only 16% in ESRD subjects.",Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1804864/),%,16,140506,DB00712,Flurbiprofen
,15761938,In,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,26.0,142390,DB00712,Flurbiprofen
,15761938,recoveries,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,26.0,142391,DB00712,Flurbiprofen
,15761938,recoveries,"In vivo recoveries of both probes, determined by using naproxen as retrodialysis calibrator, were 26.0 +/- 0.3 and 72.9 +/- 0.7% for dermal and subcutaneous probe, respectively.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),%,72.9,142392,DB00712,Flurbiprofen
,15761938,C(max),"After iontophoretic delivery, a gradient in mean tissue unbound concentrations was observed, with a C(max) in dermis of 8.7 +/- 0.4 microg/mL as compared with subcutaneous C(max) of 0.5 +/- 0.1 microg/mL.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],8.7,142393,DB00712,Flurbiprofen
,15761938,C(max),"After iontophoretic delivery, a gradient in mean tissue unbound concentrations was observed, with a C(max) in dermis of 8.7 +/- 0.4 microg/mL as compared with subcutaneous C(max) of 0.5 +/- 0.1 microg/mL.",Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],0.5,142394,DB00712,Flurbiprofen
,15761938,T(max),Total plasma concentration curves showed a rapid absorption phase with a T(max) of 30 min and C(max) of 1.8 +/- 0.1 microg/mL.,Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),min,30,142395,DB00712,Flurbiprofen
,15761938,C(max),Total plasma concentration curves showed a rapid absorption phase with a T(max) of 30 min and C(max) of 1.8 +/- 0.1 microg/mL.,Study of the percutaneous penetration of flurbiprofen by cutaneous and subcutaneous microdialysis after iontophoretic delivery in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761938/),[μg] / [ml],1.8,142396,DB00712,Flurbiprofen
,15193725,R,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,12.55 - 16.07,145171,DB00712,Flurbiprofen
,15193725,tmigr s,"The calculated electrophoretic parameters of the analytes were as follows: electrophoretic mobility, micorep(-)-R = -0.75 x 10(-4) to -0.30 x 10(-4) cm2/Vs; micorep(+)-S = -0.83 -(-0.38) cm2/Vs and electroosmotic mobility, microEOF = 2.35 x 10(-4) cm2/Vs, migration times, tmigr R = 12.55 - 16.07 min; tmigr s = 13.08 - 16.9 min, resolution factors, RS = 1.88 - 3.70 and chiral selectivity, alpha = 1.16 - 1.34.",High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),min,13.08 - 16.9,145172,DB00712,Flurbiprofen
,15193725,Recovery,Recovery of the enantiomers from serum was about 90%.,High performance capillary electrophoresis for determination of the enantiomers of 2-arylpropionic acid derivatives in human serum. Pharmacokinetic studies of ketoprofen enantiomers following administration of standard and sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193725/),%,90,145173,DB00712,Flurbiprofen
,8054251,oral clearance (CLo),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],11.0,145184,DB00712,Flurbiprofen
,8054251,renal clearance (CLR),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),[l] / [h],7.9,145185,DB00712,Flurbiprofen
,8054251,percent excreted unchanged,"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),%,72,145186,DB00712,Flurbiprofen
,8054251,fraction unbound (fu),"In the non-NSAID control portion of the study, MTX oral clearance (CLo) was 11.0 +/- 3.9 l h-1, renal clearance (CLR) was 7.9 +/- 2.8 l h-1, percent excreted unchanged was 72 +2- 19% and fraction unbound (fu) was 0.54 +/- 0.11.","Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054251/),,0.54,145187,DB00712,Flurbiprofen
,18072715,EC50,"In the in vitro inhibition assay, all prodrugs except for the prodrug with the longest alkyl side chain ( 6e) were effective as inhibitors of [F-18]FDDNP binding to Abeta fibrils with EC50 values in the 10-300 nM range.","Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18072715/),nM,10-300,148236,DB00712,Flurbiprofen
,20444019,drug loading,Niosomes of FBP showed a drug loading of 92.0 +/- 0.7% and the intravenous administration of the FBP niosomes to dairy cattle did not produce any immunological reaction associated to niosomal components.,The disposition of free and niosomally encapsulated Rac-flurbiprofen in dairy bovines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444019/),%,92.0,150287,DB00712,Flurbiprofen
more,18472314,extraction recoveries,"The extraction recoveries were more than 84.5%, the accuracies were within +/-3.8%, and the intra- and inter-day precisions were less than 10.1% in all cases.",Cloud point extraction-HPLC method for determination and pharmacokinetic study of flurbiprofen in rat plasma after oral and transdermal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18472314/),%,84.5,156081,DB00712,Flurbiprofen
,34256101,half-life,"Flurbiprofen is widely used as an oral formulation (tablet dosage form) to control pain in spondylitis; however, owing to its short half-life (3.9 h), need for frequent dosing (four times daily), and abdominal discomfort, patient compliance remains extremely poor.",Transdermal delivery of flurbiprofen from polyoxypropylene-polyoxyethylene block copolymer stabilized reduced graphene oxide to manage pain in spondylitis: In vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256101/),h,3.9,161096,DB00712,Flurbiprofen
,19243632,Cmax,"The Cmax of the B1 formulation was 38.67 +/- 2.77 microg/ml, which was significantly higher than the A1 formulation (Cmax = 21.79 +/- 2.96 microg/ml).","Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243632/),[μg] / [ml],38.67,166096,DB00712,Flurbiprofen
,19243632,Cmax,"The Cmax of the B1 formulation was 38.67 +/- 2.77 microg/ml, which was significantly higher than the A1 formulation (Cmax = 21.79 +/- 2.96 microg/ml).","Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19243632/),[μg] / [ml],21.79,166097,DB00712,Flurbiprofen
,2715375,plasma elimination half-life,The plasma elimination half-life of FB during early lactation was slightly prolonged (mean 4.8 hrs) as compared to reported values for normal adult men.,Flurbiprofen in post-partum women: plasma and breast milk disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715375/),h,4.8,166630,DB00712,Flurbiprofen
,8018462,AUC,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),[μg] / [ml],55.2,170490,DB00712,Flurbiprofen
,8018462,AUC,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),[μg] / [ml],44.6,170491,DB00712,Flurbiprofen
,8018462,elimination half-life,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),h,5.6,170492,DB00712,Flurbiprofen
,8018462,elimination half-life,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),h,4.0,170493,DB00712,Flurbiprofen
,8018462,mean residence time,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),h,7.5,170494,DB00712,Flurbiprofen
,8018462,mean residence time,Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen.,Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018462/),h,5.7,170495,DB00712,Flurbiprofen
,25039470,peak plasma concentration (Cmax),"From the pharmacokinetic evaluation, the control tablets produced peak plasma concentration (Cmax) of 9140.84 ± 614.36 ng/ml at 3 h Tmax and solid dispersion tablets showed Cmax = 11 445.46 ± 149.23 ng/ml at 2 h Tmax.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),[ng] / [ml],9140.84,176828,DB00712,Flurbiprofen
,25039470,Cmax,"From the pharmacokinetic evaluation, the control tablets produced peak plasma concentration (Cmax) of 9140.84 ± 614.36 ng/ml at 3 h Tmax and solid dispersion tablets showed Cmax = 11 445.46 ± 149.23 ng/ml at 2 h Tmax.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),[ng] / [ml],11 445.46,176829,DB00712,Flurbiprofen
,25039470,area under the curve,"The area under the curve for the control and solid dispersion tablets was 31 495.16 ± 619.92 and 43 126.52 ± 688.89 ng h/ml and the mean resident time was 3.99 and 3.68 h, respectively.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),[h·ng] / [ml],31 495.16,176830,DB00712,Flurbiprofen
,25039470,area under the curve,"The area under the curve for the control and solid dispersion tablets was 31 495.16 ± 619.92 and 43 126.52 ± 688.89 ng h/ml and the mean resident time was 3.99 and 3.68 h, respectively.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),[h·ng] / [ml],43 126.52,176831,DB00712,Flurbiprofen
,25039470,resident time,"The area under the curve for the control and solid dispersion tablets was 31 495.16 ± 619.92 and 43 126.52 ± 688.89 ng h/ml and the mean resident time was 3.99 and 3.68 h, respectively.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),h,3.99,176832,DB00712,Flurbiprofen
,25039470,resident time,"The area under the curve for the control and solid dispersion tablets was 31 495.16 ± 619.92 and 43 126.52 ± 688.89 ng h/ml and the mean resident time was 3.99 and 3.68 h, respectively.",Formulation and pharmacokinetics of gelucire solid dispersions of flurbiprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25039470/),h,3.68,176833,DB00712,Flurbiprofen
,3444752,peak plasma flurbiprofen concentration,"The average peak plasma flurbiprofen concentration, 15 micrograms/ml, occurred at 1.5 hours, and the harmonic mean half-life of the drug was 5.8 hours.",Excretion of flurbiprofen into breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3444752/),[μg] / [ml],15,177069,DB00712,Flurbiprofen
,3444752,half-life,"The average peak plasma flurbiprofen concentration, 15 micrograms/ml, occurred at 1.5 hours, and the harmonic mean half-life of the drug was 5.8 hours.",Excretion of flurbiprofen into breast milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3444752/),h,5.8,177070,DB00712,Flurbiprofen
,3444752,peak milk concentration,"The average peak milk concentration of flurbiprofen was 0.09 microgram/ml, and the maximum recovery of the dose in breast milk was only 0.07%.",Excretion of flurbiprofen into breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3444752/),[μg] / [ml],0.09,177071,DB00712,Flurbiprofen
,3444752,maximum recovery,"The average peak milk concentration of flurbiprofen was 0.09 microgram/ml, and the maximum recovery of the dose in breast milk was only 0.07%.",Excretion of flurbiprofen into breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3444752/),%,0.07,177072,DB00712,Flurbiprofen
,2324964,dose turnover rate,"At 1 min after the dose administration, drug was eluted from the donor chamber at a dose turnover rate of 12%/min.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),[%] / [min],12,179037,DB00712,Flurbiprofen
,2324964,ocular bioavailability,"Using this chamber device, the ocular bioavailability via corneal absorption ranged between 5 and 16% for solution formulations, whereas the ocular bioavailability for the suspension formulations was less than 0.3%.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),%,5 and 16,179038,DB00712,Flurbiprofen
less,2324964,ocular bioavailability,"Using this chamber device, the ocular bioavailability via corneal absorption ranged between 5 and 16% for solution formulations, whereas the ocular bioavailability for the suspension formulations was less than 0.3%.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),%,0.3,179039,DB00712,Flurbiprofen
,18579348,transdermal permeation rate,"The transdermal permeation rate of flurbiprofen across the rat abdominal skin from binary solvent mixture composition of propylene glycol (PG):isopropyl alcohol (IPA) (30:70%, v/v) was 98.88 microg/cm(2)/h, significantly higher than other binary solvent mixtures.",Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18579348/),[μg] / [cm(2)·h],98.88,180377,DB00712,Flurbiprofen
,18579348,steady state plasma concentration,"The corresponding steady state plasma concentration, 0.71 microg/ml, was much lower than required steady state plasma concentration of 3-5 microg/ml.",Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18579348/),[μg] / [ml],0.71,180378,DB00712,Flurbiprofen
,18579348,steady state plasma concentration,"The corresponding steady state plasma concentration, 0.71 microg/ml, was much lower than required steady state plasma concentration of 3-5 microg/ml.",Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18579348/),[μg] / [ml],3-5,180379,DB00712,Flurbiprofen
,22845842,drug release,The optimized formulation showed negligible drug release (7.26 ± 0.05%) in the initial lag period followed by progressive release (99.27 ± 0.46%) for 24 h.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),%,7.26,180400,DB00712,Flurbiprofen
,22845842,drug release,The optimized formulation showed negligible drug release (7.26 ± 0.05%) in the initial lag period followed by progressive release (99.27 ± 0.46%) for 24 h.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),,99,180401,DB00712,Flurbiprofen
,22845842,C(max),The C(max) of colon targeted tablets was 10792.62 ng/mL at T(max) 10 h where as in case of immediate release tablets the C(max) was 15684.79 ng/mL at T(max) 3 h signifies the ability of compression coated tablets to target the colon.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),[ng] / [ml],10792.62,180402,DB00712,Flurbiprofen
,22845842,T(max),The C(max) of colon targeted tablets was 10792.62 ng/mL at T(max) 10 h where as in case of immediate release tablets the C(max) was 15684.79 ng/mL at T(max) 3 h signifies the ability of compression coated tablets to target the colon.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),h,10,180403,DB00712,Flurbiprofen
,22845842,C(max),The C(max) of colon targeted tablets was 10792.62 ng/mL at T(max) 10 h where as in case of immediate release tablets the C(max) was 15684.79 ng/mL at T(max) 3 h signifies the ability of compression coated tablets to target the colon.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),[ng] / [ml],15684.79,180404,DB00712,Flurbiprofen
,22845842,T(max),The C(max) of colon targeted tablets was 10792.62 ng/mL at T(max) 10 h where as in case of immediate release tablets the C(max) was 15684.79 ng/mL at T(max) 3 h signifies the ability of compression coated tablets to target the colon.,"Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22845842/),h,3,180405,DB00712,Flurbiprofen
up to,22595132,% drug entrapment,The mean particle size was found to be in the range of 5.18-9.74 μm with good % drug entrapment up to 80.97%.,"Intra-articular delivery of genipin cross-linked chitosan microspheres of flurbiprofen: preparation, characterization, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595132/),%,80.97,180430,DB00712,Flurbiprofen
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0.310,187756,DB00712,Flurbiprofen
,8509997,renal clearance,"MTX renal clearance was nonlinear, increasing from 0.310 to 0.434 ml/min over the concentration range studied.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),[ml] / [min],0,187757,DB00712,Flurbiprofen
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,0.933,187758,DB00712,Flurbiprofen
,8509997,excretion ratios,"Corresponding excretion ratios increased from 0.933 to 1.52, indicative of MTX renal elimination involving the processes of filtration, secretion and reabsorption.",Characterization of methotrexate elimination and interaction with indomethacin and flurbiprofen in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8509997/),,1.52,187759,DB00712,Flurbiprofen
,26017285,peak plasma concentration (C max),"From the pharmacokinetic evaluation, core mini-tablets producing peak plasma concentration (C max) was 14,677.51 ± 12.16 ng/ml at 3 h T max and pulsatile colonic tablets showed C max = 12,374.67 ± 16.72 ng/ml at 12 h T max.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),[ng] / [ml],"14,677.51",190300,DB00712,Flurbiprofen
,26017285,C max,"From the pharmacokinetic evaluation, core mini-tablets producing peak plasma concentration (C max) was 14,677.51 ± 12.16 ng/ml at 3 h T max and pulsatile colonic tablets showed C max = 12,374.67 ± 16.72 ng/ml at 12 h T max.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),[ng] / [ml],"12,374.67",190301,DB00712,Flurbiprofen
,26017285,area under the curve,"The area under the curve for the mini and pulsatile tablets was 41,238.52 and 72,369.24 ng-h/ml, and the mean resident time was 3.43 and 10.61 h, respectively.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),[ng-h] / [ml],"41,238.52",190302,DB00712,Flurbiprofen
,26017285,area under the curve,"The area under the curve for the mini and pulsatile tablets was 41,238.52 and 72,369.24 ng-h/ml, and the mean resident time was 3.43 and 10.61 h, respectively.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),[ng-h] / [ml],"72,369.24",190303,DB00712,Flurbiprofen
,26017285,resident time,"The area under the curve for the mini and pulsatile tablets was 41,238.52 and 72,369.24 ng-h/ml, and the mean resident time was 3.43 and 10.61 h, respectively.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),h,3.43,190304,DB00712,Flurbiprofen
,26017285,resident time,"The area under the curve for the mini and pulsatile tablets was 41,238.52 and 72,369.24 ng-h/ml, and the mean resident time was 3.43 and 10.61 h, respectively.",A Novel Approach to Flurbiprofen Pulsatile Colonic Release: Formulation and Pharmacokinetics of Double-Compression-Coated Mini-Tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017285/),h,10.61,190305,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],114.5,190526,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],136.4,190527,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],121.4,190528,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],128.9,190529,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],22.0,190530,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],24.2,190531,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],46.5,190532,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],27.6,190533,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],25.3,190534,DB00712,Flurbiprofen
,16755363,Total body clearance (ClB),"Total body clearance (ClB) of (S)-(+)-FBP was higher in calves than in cows (114.5, 136.4, 121.4, 128.9 microg/ml vs 22.0, 24.2, 46.5 microg/ml and 27.6, 25.3, 34.6 microg/ml).",Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16755363/),[μg] / [ml],34.6,190535,DB00712,Flurbiprofen
more,17452028,extraction efficiency,The extraction efficiency was more than 79.5% for each of the six analytes.,"Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452028/),%,79.5,196786,DB00712,Flurbiprofen
,8668659,recoveries,"The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,68.2,197363,DB00712,Flurbiprofen
,8668659,recoveries,"The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,66.5,197364,DB00712,Flurbiprofen
,8668659,relatively loss,"The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,66.1,197365,DB00712,Flurbiprofen
,8668659,relatively loss,"The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen.",Intravenous microdialysis in the mouse and the rat: development and pharmacokinetic application of a new probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668659/),%,60.9,197366,DB00712,Flurbiprofen
,7946972,Tmax,A significant difference was observed in the Tmax of the active (S)-enantiomer by both administration routes (sq 4 h and po 1 h).,Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946972/),h,4,199487,DB00712,Flurbiprofen
,7946972,Tmax,A significant difference was observed in the Tmax of the active (S)-enantiomer by both administration routes (sq 4 h and po 1 h).,Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946972/),h,1,199488,DB00712,Flurbiprofen
,7650070,Maximum concentrations of the NSAID in plasma (Cmax),"Maximum concentrations of the NSAID in plasma (Cmax) were much lower after a single application of the topical 40 mg flurbiprofen patch than after a single oral dose of 50 mg of the NSAID (mean +/- SD: 43 +/- 16 ng/ml versus 5999 +/- 1300 ng/ml, respectively).",Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650070/),[ng] / [ml],43,200538,DB00712,Flurbiprofen
,7650070,Maximum concentrations of the NSAID in plasma (Cmax),"Maximum concentrations of the NSAID in plasma (Cmax) were much lower after a single application of the topical 40 mg flurbiprofen patch than after a single oral dose of 50 mg of the NSAID (mean +/- SD: 43 +/- 16 ng/ml versus 5999 +/- 1300 ng/ml, respectively).",Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650070/),[ng] / [ml],5999,200539,DB00712,Flurbiprofen
,7650070,Cmax,"After repeated application of the topical patch, Cmax increased only slightly to 103 +/- 57 ng/ml.",Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650070/),[ng] / [ml],103,200540,DB00712,Flurbiprofen
,7650070,relative bioavailability,"The mean relative bioavailability of flurbiprofen from the patch was 3.5 +/- 1.7%, calculated from plasma area under the curve data and 4.4 +/- 2.8% from urinary excretion data.",Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650070/),%,3.5,200541,DB00712,Flurbiprofen
,7650070,relative bioavailability,"The mean relative bioavailability of flurbiprofen from the patch was 3.5 +/- 1.7%, calculated from plasma area under the curve data and 4.4 +/- 2.8% from urinary excretion data.",Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650070/),%,4.4,200542,DB00712,Flurbiprofen
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.9,201410,DB00712,Flurbiprofen
,16432273,elimination half-life,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),h,3.5,201411,DB00712,Flurbiprofen
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],57,201412,DB00712,Flurbiprofen
,16432273,total AUC,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[μg] / [h·ml],55,201413,DB00712,Flurbiprofen
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],32.9,201414,DB00712,Flurbiprofen
,16432273,oral clearance,"Mean kinetic variables for flurbiprofen with either placebo or G biloba were elimination half-life, 3.9 versus 3.5 hours; total AUC, 57 versus 55 microg/mL h; and oral clearance, 32.9 versus 31.6 mL/min.","Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16432273/),[ml] / [min],31.6,201415,DB00712,Flurbiprofen
,10370213,maximum solubility,The maximum solubility of flurbiprofen in the microemulsion system was found to be 10 mg/ml.,Preparation and evaluation of flurbiprofen-loaded microemulsion for parenteral delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10370213/),[mg] / [ml],10,202469,DB00712,Flurbiprofen
,2777421,relative bioavailability,"Area under the curve and half-time in terminal phase were similar, with the granule relative bioavailability of 0.98.",Single-dose pharmacokinetics of flurbiprofen granules and tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777421/),,0.98,207249,DB00712,Flurbiprofen
,1800701,Cmax,"After the buccal treatment, mean Cmax and Tmax values were 0.751 micrograms/mL and 41 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[μg] / [ml],0.751,209523,DB00712,Flurbiprofen
,1800701,Tmax,"After the buccal treatment, mean Cmax and Tmax values were 0.751 micrograms/mL and 41 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),min,41,209524,DB00712,Flurbiprofen
,1800701,Cmax,"Average Cmax and Tmax values after the oral treatment were 10.8 micrograms/mL and 32 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[μg] / [ml],10.8,209525,DB00712,Flurbiprofen
,1800701,Tmax,"Average Cmax and Tmax values after the oral treatment were 10.8 micrograms/mL and 32 min, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),min,32,209526,DB00712,Flurbiprofen
,1800701,dose-corrected AUCs,"Mean dose-corrected AUCs were 0.0854 and 0.811 (micrograms.h/mL)/mg for the buccal and the oral treatments, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[h·μgrams] / [mg·ml)],0.0854,209527,DB00712,Flurbiprofen
,1800701,dose-corrected AUCs,"Mean dose-corrected AUCs were 0.0854 and 0.811 (micrograms.h/mL)/mg for the buccal and the oral treatments, respectively.",Absorption of flurbiprofen through human buccal mucosa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),[h·μgrams] / [mg·ml)],0.811,209528,DB00712,Flurbiprofen
,1800701,ka,"Analysis, by ELRM, of the plasma concentration-time data obtained after the buccal treatment indicated first-order absorption, with a mean ka value of 3.9 +/- 2.2 h-1.",Absorption of flurbiprofen through human buccal mucosa. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),1/[h],3.9,209529,DB00712,Flurbiprofen
,1800701,ka,"This value was significantly different (0.05 greater than p greater than 0.02) from the ka after oral treatment (7.89 +/- 5.2 h-1), obtained from the triexponential fitting of the oral plasma data.",Absorption of flurbiprofen through human buccal mucosa. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800701/),1/[h],7.89,209530,DB00712,Flurbiprofen
,33609057,Tmax,Tmax for both products is 0.3 hours.,"Evaluation of bioequivalence of two flurbiprofen axetil injections: A randomized, open-label, double-cycle, and crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33609057/),h,0.3,209593,DB00712,Flurbiprofen
,33609057,adverse event rate,The adverse event rate of the test product was 8.3% and no serious adverse events (SAE) occurred in this clinical study.,"Evaluation of bioequivalence of two flurbiprofen axetil injections: A randomized, open-label, double-cycle, and crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33609057/),%,8.3,209594,DB00712,Flurbiprofen
,31194730,AUCo/AUCp plasma,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.64-1.66,211062,DB00712,Flurbiprofen
,31194730,AUCo/AUCp CSF,"The model was also able to describe disease-mediated changes in neonates and young children (<3m postnatal age) related to meningitis and sepsis (range AUCo/AUCp plasma: 1.64-1.66, range AUCo/AUCp CSF: 1.43-1.73).",Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194730/),,1.43-1.73,211063,DB00712,Flurbiprofen
>,12946535,extraction efficiency,The mean extraction efficiency was >95%.,Stereospecific high-performance liquid chromatographic analysis of flurbiprofen: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12946535/),%,95,212005,DB00712,Flurbiprofen
,6533296,Plasma clearance,"Plasma clearance values of flurbiprofen were 6.77 and 7.87 ml/min, after 6-mg and 208-micrograms intravenous doses, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),[ml] / [min],6.77,216797,DB00712,Flurbiprofen
,6533296,Plasma clearance,"Plasma clearance values of flurbiprofen were 6.77 and 7.87 ml/min, after 6-mg and 208-micrograms intravenous doses, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),[ml] / [min],7.87,216798,DB00712,Flurbiprofen
,6533296,systemic,"The systemic and ocular distribution half-lives of flurbiprofen were 12 min and 15 min, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),min,12,216799,DB00712,Flurbiprofen
,6533296,ocular distribution half-lives,"The systemic and ocular distribution half-lives of flurbiprofen were 12 min and 15 min, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),min,15,216800,DB00712,Flurbiprofen
,6533296,plasma elimination half-life,The plasma elimination half-life was 74 min and the aqueous humor elimination half-life was 93 min.,Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),min,74,216801,DB00712,Flurbiprofen
,6533296,aqueous humor elimination half-life,The plasma elimination half-life was 74 min and the aqueous humor elimination half-life was 93 min.,Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),min,93,216802,DB00712,Flurbiprofen
,6533296,ocular bioavailabilities,"The ocular bioavailabilities of the 75-micrograms and 150-micrograms topical flurbiprofen doses were 10% and 7%, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),%,10,216803,DB00712,Flurbiprofen
,6533296,ocular bioavailabilities,"The ocular bioavailabilities of the 75-micrograms and 150-micrograms topical flurbiprofen doses were 10% and 7%, respectively.",Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),%,7,216804,DB00712,Flurbiprofen
,6533296,Systemic bioavailability,Systemic bioavailability after topical administration of 225 micrograms of flurbiprofen was 74%.,Ocular and systemic bioavailability of ophthalmic flurbiprofen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533296/),%,74,216805,DB00712,Flurbiprofen
,8668672,area under the unbound plasma concentration-time profile of flurbiprofen (AUCu),"The area under the unbound plasma concentration-time profile of flurbiprofen (AUCu), determined by microdialysis sampling was somewhat smaller (-19%, p = 0.666) in the rats undergoing simultaneous serial blood sampling (2.21 +/- 0.36 micrograms.h/ml) as compared to the rats undergoing microdialysis sampling only (2.73 +/- 0.60 micrograms.h/ml).",Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668672/),[h·μg] / [ml],2.21,217551,DB00712,Flurbiprofen
,8668672,area under the unbound plasma concentration-time profile of flurbiprofen (AUCu),"The area under the unbound plasma concentration-time profile of flurbiprofen (AUCu), determined by microdialysis sampling was somewhat smaller (-19%, p = 0.666) in the rats undergoing simultaneous serial blood sampling (2.21 +/- 0.36 micrograms.h/ml) as compared to the rats undergoing microdialysis sampling only (2.73 +/- 0.60 micrograms.h/ml).",Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668672/),[h·μg] / [ml],2.73,217552,DB00712,Flurbiprofen
,8668672,plasma binding,Comparison of total and unbound concentrations of flurbiprofen showed an in vivo plasma binding varying between 99.5% at low and 98.0% at high total flurbiprofen plasma concentrations.,Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668672/),%,99.5,217553,DB00712,Flurbiprofen
,8668672,plasma binding,Comparison of total and unbound concentrations of flurbiprofen showed an in vivo plasma binding varying between 99.5% at low and 98.0% at high total flurbiprofen plasma concentrations.,Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668672/),%,98.0,217554,DB00712,Flurbiprofen
,8668672,Plasma binding,Plasma binding of flurbiprofen determined in vitro over the same concentration range was higher (99.5-99.9%) but also concentration-dependent.,Concentration-dependent plasma protein binding of flurbiprofen in the rat: an in vivo microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668672/),%,99.5,217555,DB00712,Flurbiprofen
,23700219,zeta potential,"The zeta potential was -26.8 mV, the mean volume particle diameter was 134 nm, drug encapsulation efficiency was 53.3 ± 3.6 % and concentration was 1.5 mg/mL.",Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly(alkyl-cyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700219/),mv,-,221785,DB00712,Flurbiprofen
,23700219,zeta potential,"The zeta potential was -26.8 mV, the mean volume particle diameter was 134 nm, drug encapsulation efficiency was 53.3 ± 3.6 % and concentration was 1.5 mg/mL.",Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly(alkyl-cyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700219/),mv,26.8,221786,DB00712,Flurbiprofen
,23700219,relative bioavailability,"As compared to the flurbiprofen suspension, 211.6 % relative bioavailability was observed for flurbiprofen nanoparticles.",Enhanced bioavailability of orally administered flurbiprofen by combined use of hydroxypropyl-cyclodextrin and poly(alkyl-cyanoacrylate) nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23700219/),%,211.6,221787,DB00712,Flurbiprofen
,25145138,extraction recoveries,The extraction recoveries of flurbiprofen from human plasma were between 93.6 and 98.6%.,Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),%,93.6 and 98.6,225562,DB00712,Flurbiprofen
,25145138,LOD,"The LOD and LOQ of flurbiprofen were 0.03 and 0.10 microg/mL, respectively.",Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),[μg] / [ml],0.03,225563,DB00712,Flurbiprofen
,25145138,LOQ,"The LOD and LOQ of flurbiprofen were 0.03 and 0.10 microg/mL, respectively.",Determination of flurbiprofen in human plasma by gas chromatography with mass spectrometry and its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25145138/),[μg] / [ml],0.10,225564,DB00712,Flurbiprofen
,20191350,maximum solubility,"The solubility of flurbiprofen was the highest in the mixed system containing 1.3 mM beta-CD and 0.3% w/v Tween 80, and the maximum solubility of 160 microg/mL was achieved.",Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20191350/),[μg] / [ml],160,226296,DB00712,Flurbiprofen
,20840447,apparent bioavailability,The apparent bioavailability of oral flurbiprofen syrup was 81%.,Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840447/),%,81,228946,DB00712,Flurbiprofen
,20840447,clearance (CL),The estimated clearance (CL) was 0.96l h(-1) 70 kg(-1) .,Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840447/),[l] / [70·h·kg],0.96,228947,DB00712,Flurbiprofen
,20840447,volume of distribution at steady state (V(ss) ),The estimated volume of distribution at steady state (V(ss) ) was 8.1 l 70 kg(-1) .,Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840447/),[l] / [70·kg],8.1,228948,DB00712,Flurbiprofen
,24038489,apparent oral clearance,"In patients with glomerulonephritis, the apparent oral clearance of fexofenadine (representing transporter activity) was 58.8 ± 34.4 L/hour, documenting a 40% reduction compared with previous data in healthy controls.",In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24038489/),[l] / [h],58.8,231001,DB00712,Flurbiprofen
,28963579,recovery,The recovery of flurbiprofen from vitreous samples was 92.6%.,Pharmacokinetics and efficacy of intraocular flurbiprofen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28963579/),%,92.6,237461,DB00712,Flurbiprofen
,28963579,half-life,The half-life of flurbiprofen was estimated to be 1.92 h with an elimination constant rate (K) of 0.36.,Pharmacokinetics and efficacy of intraocular flurbiprofen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28963579/),h,1.92,237462,DB00712,Flurbiprofen
,28963579,elimination constant rate (K),The half-life of flurbiprofen was estimated to be 1.92 h with an elimination constant rate (K) of 0.36.,Pharmacokinetics and efficacy of intraocular flurbiprofen. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28963579/),,0.36,237463,DB00712,Flurbiprofen
,2252842,clearance,"There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],12.6,238141,DB00712,Flurbiprofen
,2252842,clearance,"There was 50 +/- 4% inversion of (R)-ibuprofen, a figure similar to that observed in man and (R)-ibuprofen had a higher clearance (12.6 +/- 1.3 ml/min/kg) than (S)-ibuprofen (7.7 +/- 0.7 ml/min/kg; P less than 0.01).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],7.7,238142,DB00712,Flurbiprofen
,2252842,clearance,"The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],2.3,238143,DB00712,Flurbiprofen
,2252842,clearance,"The clearance of (R)-flurbiprofen after racemate (2.3 +/- 0.1 ml/min/kg) was higher than its clearance when administered alone (1.7 +/- 0.2 ml/min/kg; P less than 0.01), indicating a pharmacokinetic interaction between the enantiomers (most probably at plasma protein binding sites).",Stereoselective disposition of ibuprofen and flurbiprofen in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2252842/),[ml] / [kg·min],1.7,238144,DB00712,Flurbiprofen
,25264913,flow rate of the mobile phase,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),[μl] / [min],250,239506,DB00712,Flurbiprofen
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,1.1,239507,DB00712,Flurbiprofen
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,0.8,239508,DB00712,Flurbiprofen
,25264913,retention times,"The flow rate of the mobile phase was 250μl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively.",Simultaneous determination of flurbiprofen and its hydroxy metabolite in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25264913/),min,0.9,239509,DB00712,Flurbiprofen
below,23047652,50% inhibitory concentration (IC(50)),"The in vitro 50% inhibitory concentration (IC(50)) values for pomegranate juice and extract were below 1% (vol/vol), with no evidence of mechanism-based (irreversible) inhibition.",Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23047652/),%,1,239680,DB00712,Flurbiprofen
,2778668,AUC,A significant interaction was noticed between the enantiomers: mean AUC +/- SD of R-FL was reduced from 115.3 +/- 21.3 to 49.0 +/- 10.4 mg/L.h as a result of S-FL coadministration.,Enantiomeric interaction of flurbiprofen in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778668/),[mg] / [h·l],115.3,240705,DB00712,Flurbiprofen
,2778668,AUC,A significant interaction was noticed between the enantiomers: mean AUC +/- SD of R-FL was reduced from 115.3 +/- 21.3 to 49.0 +/- 10.4 mg/L.h as a result of S-FL coadministration.,Enantiomeric interaction of flurbiprofen in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778668/),[mg] / [h·l],49.0,240706,DB00712,Flurbiprofen
,2778668,AUC,A trend towards reduced S-FL plasma concentration was also evident when the enantiomer was given as the racemate [mean AUC +/- SD; 176.8 +/- 37.7 racemate versus 241.4 +/- 86.2 mg/L.h alone].,Enantiomeric interaction of flurbiprofen in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778668/),[mg] / [h·l],176.8,240707,DB00712,Flurbiprofen
,2778668,AUC,A trend towards reduced S-FL plasma concentration was also evident when the enantiomer was given as the racemate [mean AUC +/- SD; 176.8 +/- 37.7 racemate versus 241.4 +/- 86.2 mg/L.h alone].,Enantiomeric interaction of flurbiprofen in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778668/),[mg] / [h·l],241.4,240708,DB00712,Flurbiprofen
,20686524,AUC,The AUC of FB administered as FB cubosome F2 was 486.36+/-38.93 ng.,Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20686524/),ng,486.36,242770,DB00712,Flurbiprofen
,34086139,particle,"The particle size, polydispersity index and zeta potential values of optimum NS were determined as 237.7 ± 6.8 nm, 0.133 ± 0.030 and - 30.4 ± 0.7 mV, respectively.","Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),nm,237.7,246830,DB00712,Flurbiprofen
,34086139,polydispersity index,"The particle size, polydispersity index and zeta potential values of optimum NS were determined as 237.7 ± 6.8 nm, 0.133 ± 0.030 and - 30.4 ± 0.7 mV, respectively.","Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),mv,0.133,246831,DB00712,Flurbiprofen
,34086139,zeta potential,"The particle size, polydispersity index and zeta potential values of optimum NS were determined as 237.7 ± 6.8 nm, 0.133 ± 0.030 and - 30.4 ± 0.7 mV, respectively.","Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),mv,-,246832,DB00712,Flurbiprofen
,34086139,zeta potential,"The particle size, polydispersity index and zeta potential values of optimum NS were determined as 237.7 ± 6.8 nm, 0.133 ± 0.030 and - 30.4 ± 0.7 mV, respectively.","Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),mv,30.4,246833,DB00712,Flurbiprofen
,34086139,percentage permeated amount,The percentage permeated amount of FB from FB-NS gel (8.40%) was also found to be higher than the physical mixture (5.25%) and coarse suspension (reference) (2.08%) gels.,"Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),%,8.40,246834,DB00712,Flurbiprofen
,34086139,percentage permeated amount,The percentage permeated amount of FB from FB-NS gel (8.40%) was also found to be higher than the physical mixture (5.25%) and coarse suspension (reference) (2.08%) gels.,"Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),%,5.25,246835,DB00712,Flurbiprofen
,34086139,percentage permeated amount,The percentage permeated amount of FB from FB-NS gel (8.40%) was also found to be higher than the physical mixture (5.25%) and coarse suspension (reference) (2.08%) gels.,"Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086139/),%,2.08,246836,DB00712,Flurbiprofen
,8866042,Cmax,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],9.88,250506,DB00712,Flurbiprofen
,8866042,Cmax,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],11.36,250507,DB00712,Flurbiprofen
,8866042,AUC0-48,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[h·mg] / [l],120.78,250508,DB00712,Flurbiprofen
,8866042,AUC0-48,Cmax (+/-SE) increased from 9.88 +/- 0.48 mg L-1 (fasting) to 11.36 +/- 0.88 mg L-1 (postprandial) and AUC0-48 (+/-SE) increased from 120.78 +/- 9.64 mg h L-1 (fasting) to 149.73 +/- 12.24 mg h L-1 (postprandial).,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[h·mg] / [l],149.73,250509,DB00712,Flurbiprofen
,8866042,time to peak (tmax),The mean (+/-SE) time to peak (tmax) was also significantly delayed from 3.85 +/- 0.27 h to 8.70 +/- 0.89 h.,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),h,3.85,250510,DB00712,Flurbiprofen
,8866042,time to peak (tmax),The mean (+/-SE) time to peak (tmax) was also significantly delayed from 3.85 +/- 0.27 h to 8.70 +/- 0.89 h.,The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),h,8.70,250511,DB00712,Flurbiprofen
,8866042,concentration of the first peak (Cpeak 1),"Although food did not affect the bioavailability of this formulation, there was a statistically significant increase in the mean (+/-SE) concentration of the first peak (Cpeak 1) from 14.21 +/- 1.38 mg L-1 (fasting) to 20.14 +/- 1.38 mg L-1 (with food).",The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],14.21,250512,DB00712,Flurbiprofen
,8866042,concentration of the first peak (Cpeak 1),"Although food did not affect the bioavailability of this formulation, there was a statistically significant increase in the mean (+/-SE) concentration of the first peak (Cpeak 1) from 14.21 +/- 1.38 mg L-1 (fasting) to 20.14 +/- 1.38 mg L-1 (with food).",The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866042/),[mg] / [l],20.14,250513,DB00712,Flurbiprofen
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00712,Flurbiprofen
,14712475,t(50%),"Surprisingly, there was no significant difference between t(50%) of the three formulations (21.6 +/- 1.1 h).","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,21.6,253124,DB00712,Flurbiprofen
,14712475,C(max),"There was a rapid release of R-FL, S-FL, or rac-FL followed by a slower one and C(max) values were observed after 2.5 +/- 2.5, 8.3 +/- 3.4 and 8.86 +/- 3.6 h of (-)-R-FL, (+)-S-FL, and rac-FL, respectively, after nanoparticle administration.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,2.5,253125,DB00712,Flurbiprofen
,14712475,C(max),"There was a rapid release of R-FL, S-FL, or rac-FL followed by a slower one and C(max) values were observed after 2.5 +/- 2.5, 8.3 +/- 3.4 and 8.86 +/- 3.6 h of (-)-R-FL, (+)-S-FL, and rac-FL, respectively, after nanoparticle administration.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,8.3,253126,DB00712,Flurbiprofen
,14712475,C(max),"There was a rapid release of R-FL, S-FL, or rac-FL followed by a slower one and C(max) values were observed after 2.5 +/- 2.5, 8.3 +/- 3.4 and 8.86 +/- 3.6 h of (-)-R-FL, (+)-S-FL, and rac-FL, respectively, after nanoparticle administration.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,8.86,253127,DB00712,Flurbiprofen
,14712475,mean retention time (MRT),"PLGA nanoparticles increased the mean retention time (MRT) of S-FL by 2.7-fold, from 6.8 to 16.3 h, compared to rac-FL.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,6.8,253128,DB00712,Flurbiprofen
,14712475,mean retention time (MRT),"PLGA nanoparticles increased the mean retention time (MRT) of S-FL by 2.7-fold, from 6.8 to 16.3 h, compared to rac-FL.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),h,16.3,253129,DB00712,Flurbiprofen
,14712475,concentration,"Although the dose of rac-FL-PLGA nanoparticles was only 2.5 times higher than that of the drug in the suspension, the mean (+)-S-FL concentration after 12 h was 3.4 times higher in the case of nanoparticles than after the free form, 10.35 +/- 1.6 and 3.04 +/- 1.1 mg/l, respectively.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),,10,253130,DB00712,Flurbiprofen
,14712475,concentration,"Although the dose of rac-FL-PLGA nanoparticles was only 2.5 times higher than that of the drug in the suspension, the mean (+)-S-FL concentration after 12 h was 3.4 times higher in the case of nanoparticles than after the free form, 10.35 +/- 1.6 and 3.04 +/- 1.1 mg/l, respectively.","In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14712475/),,3,253131,DB00712,Flurbiprofen
,22989987,maximum concentration,"The maximum concentration in plasma was 29.44 μg/ml and 2.49 μg/ml after oral and topical administration, respectively.","Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989987/),[μg] / [ml],29.44,254768,DB00712,Flurbiprofen
,22989987,maximum concentration,"The maximum concentration in plasma was 29.44 μg/ml and 2.49 μg/ml after oral and topical administration, respectively.","Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989987/),[μg] / [ml],2.49,254769,DB00712,Flurbiprofen
,303167,highest serum concentrations,"In all 3 patients the drug was absorbed rapidly into the circulation, the highest serum concentrations of 7 microgram to 9 microgram per ml being seen in the first blood sample withdrawn 1.5 hours after administration of the dose.",Concentrations of flurbiprofen in serum and synovial fluid from patients with active rheumatoid disease: some preliminary observations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/303167/),μg,7,256815,DB00712,Flurbiprofen
,303167,highest serum concentrations,"In all 3 patients the drug was absorbed rapidly into the circulation, the highest serum concentrations of 7 microgram to 9 microgram per ml being seen in the first blood sample withdrawn 1.5 hours after administration of the dose.",Concentrations of flurbiprofen in serum and synovial fluid from patients with active rheumatoid disease: some preliminary observations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/303167/),[μg] / [ml],9,256816,DB00712,Flurbiprofen
,303167,apparent half-life,Serum concentrations fell with a mean apparent half-life of approximately 3 hours.,Concentrations of flurbiprofen in serum and synovial fluid from patients with active rheumatoid disease: some preliminary observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/303167/),h,3,256817,DB00712,Flurbiprofen
,22119666,z-average diameter,"The liquid SNEDDS, composed of Labrafil M 1944 CS/Labrasol/Trasncutol HP (12.5/80/7.5%) with 2%w/v flurbiprofen, gave a z-average diameter of about 100 nm.","Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22119666/),nm,100,266930,DB00712,Flurbiprofen
,9107541,plasma clearance (CL),"FL pharmacokinetics were highly stereospecific in control rats: plasma clearance (CL) was much higher and distribution volume (Vd) larger for R-FL (2.60 +/- 0.51 ml.min-1.kg-1 and 500 +/- 59 ml.kg-1, respectively) as compared with S-FL (CL: 0.72 +/- 0.10 ml.min-1.kg-1, Vd:312 +/- 12 ml.kg-1).",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg·min],2.60,267767,DB00712,Flurbiprofen
,9107541,distribution volume (Vd),"FL pharmacokinetics were highly stereospecific in control rats: plasma clearance (CL) was much higher and distribution volume (Vd) larger for R-FL (2.60 +/- 0.51 ml.min-1.kg-1 and 500 +/- 59 ml.kg-1, respectively) as compared with S-FL (CL: 0.72 +/- 0.10 ml.min-1.kg-1, Vd:312 +/- 12 ml.kg-1).",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg·min],2.60,267768,DB00712,Flurbiprofen
,9107541,distribution volume (Vd),"FL pharmacokinetics were highly stereospecific in control rats: plasma clearance (CL) was much higher and distribution volume (Vd) larger for R-FL (2.60 +/- 0.51 ml.min-1.kg-1 and 500 +/- 59 ml.kg-1, respectively) as compared with S-FL (CL: 0.72 +/- 0.10 ml.min-1.kg-1, Vd:312 +/- 12 ml.kg-1).",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg],500,267769,DB00712,Flurbiprofen
,9107541,CL,"FL pharmacokinetics were highly stereospecific in control rats: plasma clearance (CL) was much higher and distribution volume (Vd) larger for R-FL (2.60 +/- 0.51 ml.min-1.kg-1 and 500 +/- 59 ml.kg-1, respectively) as compared with S-FL (CL: 0.72 +/- 0.10 ml.min-1.kg-1, Vd:312 +/- 12 ml.kg-1).",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg·min],0.72,267770,DB00712,Flurbiprofen
,9107541,Vd,"FL pharmacokinetics were highly stereospecific in control rats: plasma clearance (CL) was much higher and distribution volume (Vd) larger for R-FL (2.60 +/- 0.51 ml.min-1.kg-1 and 500 +/- 59 ml.kg-1, respectively) as compared with S-FL (CL: 0.72 +/- 0.10 ml.min-1.kg-1, Vd:312 +/- 12 ml.kg-1).",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg],312,267771,DB00712,Flurbiprofen
<,9107541,Renal excretion,"Renal excretion of the R- and S-FL glucuronides was extremely small (< 0.5%), whereas biliary excretion accounted for 8.3 +/- 1.8% (R-FL glucuronide) and 14.3 +/- 2.4% (S-FL glucuronide) of the administered dose.",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),%,0.5,267772,DB00712,Flurbiprofen
,9107541,CL,"Bile-duct cannulation significantly increased CL of S-FL (0.90 +/- 0.10 ml.min-1.kg-1 compared with 0.72 +/- 0.10 ml.min-1.kg-1 in control rats, p < 0.05), whereas CL of R-FL was not affected.",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg·min],0.90,267773,DB00712,Flurbiprofen
,9107541,CL,"Bile-duct cannulation significantly increased CL of S-FL (0.90 +/- 0.10 ml.min-1.kg-1 compared with 0.72 +/- 0.10 ml.min-1.kg-1 in control rats, p < 0.05), whereas CL of R-FL was not affected.",Biliary excretion and enterohepatic cycling of R- and S-flurbiprofen in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9107541/),[ml] / [kg·min],0.72,267774,DB00712,Flurbiprofen
,16413247,clearance,"Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4.","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],29-33,272901,DB00712,Flurbiprofen
,16413247,elimination half-life,"Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4.","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,3.3-3.4,272902,DB00712,Flurbiprofen
,16413247,clearance,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],17,272903,DB00712,Flurbiprofen
,16413247,clearance,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),[ml] / [min],31,272904,DB00712,Flurbiprofen
,16413247,half-life,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,5.3,272905,DB00712,Flurbiprofen
,16413247,half-life,"However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P <.05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P <.05).","Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413247/),h,3.3,272906,DB00712,Flurbiprofen
